(Q37594779)

21 August 2017

1 reference

title

Novel factor Xa inhibitors: a patent review (English)

1 reference

21 August 2017

Modesto de Candia

1

0 references

author name string

Gianfranco Lopopolo

series ordinal

2

1 reference

21 August 2017

Cosimo Altomare

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Therapeutic Patents

21 August 2017

published in

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1535-1580

1 reference

Triggers, targets and treatments for thrombosis

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Clinical aspects of platelet inhibitors and thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Beyond heparin and warfarin: the new generation of anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

New advances in the discovery of thrombin and factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Development of new anticoagulants: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Warfarin induced skin necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Clinical practice. Heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Novel oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Combined antiplatelet and anticoagulant therapy: clinical benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Conundrums in the combined use of anticoagulants and antiplatelet drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Recent advances in the discovery and development of direct coagulation factor Xa inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Hepatic findings in long-term clinical trials of ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Structure-based design of novel potent nonpeptide thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Coagulation factor Xa inhibition: biological background and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

New anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

The use of 3D structural data in the design of specific factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

The anticoagulants market.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Small molecule coagulation cascade inhibitors in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

7-fluoroindazoles as potent and selective inhibitors of factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Selective and dual action orally active inhibitors of thrombin and factor Xa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

Dibasic (Amidinoaryl)propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903270532

10.1517/13543770903270532

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference